These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1151 related articles for article (PubMed ID: 25936945)
1. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ). Davis GD; Vasanthi AH Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945 [TBL] [Abstract][Full Text] [Related]
2. A comprehensive structure-activity analysis of protein kinase B-alpha (Akt1) inhibitors. Ajmani S; Agrawal A; Kulkarni SA J Mol Graph Model; 2010 Apr; 28(7):683-94. PubMed ID: 20153226 [TBL] [Abstract][Full Text] [Related]
3. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors. Vyas VK; Ghate M; Goel A J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201 [TBL] [Abstract][Full Text] [Related]
4. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening. Chaudhari P; Bari S Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560 [TBL] [Abstract][Full Text] [Related]
5. Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling. Aboalhaija NH; Zihlif MA; Taha MO Chem Biol Interact; 2016 Apr; 250():12-26. PubMed ID: 26954606 [TBL] [Abstract][Full Text] [Related]
6. Computational investigation of imidazo[2,1-b]oxazole derivatives as potential mutant BRAF kinase inhibitors: 3D-QSAR, molecular docking, molecular dynamics simulation, and ADMETox studies. Boutalaka M; El Bahi S; Alaqarbeh M; El Alaouy MA; Koubi Y; Khatabi KE; Maghat H; Bouachrine M; Lakhlifi T J Biomol Struct Dyn; 2024 Jul; 42(10):5268-5287. PubMed ID: 37424193 [TBL] [Abstract][Full Text] [Related]
7. Discovery of Akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents. Chuang CH; Cheng TC; Leu YL; Chuang KH; Tzou SC; Chen CS Int J Mol Sci; 2015 Feb; 16(2):3202-12. PubMed ID: 25648320 [TBL] [Abstract][Full Text] [Related]
8. AKT Inhibitors: The Road Ahead to Computational Modeling-Guided Discovery. Halder AK; Cordeiro MNDS Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920446 [TBL] [Abstract][Full Text] [Related]
9. Application of GA-MLR for QSAR Modeling of the Arylthioindole Class of Tubulin Polymerization Inhibitors as Anticancer Agents. Ahmadi S; Habibpour E Anticancer Agents Med Chem; 2017; 17(4):552-565. PubMed ID: 27528182 [TBL] [Abstract][Full Text] [Related]
10. Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets. Shahin R; Swellmeen L; Shaheen O; Aboalhaija N; Habash M J Comput Aided Mol Des; 2016 Jan; 30(1):39-68. PubMed ID: 26685860 [TBL] [Abstract][Full Text] [Related]
11. QSAR and 3D-QSAR models in the field of tubulin inhibitors as anticancer agents. Marzaro G; Chilin A Curr Top Med Chem; 2014; 14(20):2253-62. PubMed ID: 25434357 [TBL] [Abstract][Full Text] [Related]
12. Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: toward the discovery of novel Akt1 inhibitors. Zhan W; Li D; Che J; Zhang L; Yang B; Hu Y; Liu T; Dong X Eur J Med Chem; 2014 Mar; 75():11-20. PubMed ID: 24508830 [TBL] [Abstract][Full Text] [Related]
13. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors. Zeng H; Zhang H J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293 [TBL] [Abstract][Full Text] [Related]
14. In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors. Asadollahi-Baboli M Mol Divers; 2016 Aug; 20(3):729-39. PubMed ID: 27209475 [TBL] [Abstract][Full Text] [Related]
15. 3D QSAR studies, molecular docking and ADMET evaluation, using thiazolidine derivatives as template to obtain new inhibitors of PIM1 kinase. Aouidate A; Ghaleb A; Ghamali M; Ousaa A; Choukrad M; Sbai A; Bouachrine M; Lakhlifi T Comput Biol Chem; 2018 Jun; 74():201-211. PubMed ID: 29635214 [TBL] [Abstract][Full Text] [Related]
16. In silico studies on potential MCF-7 inhibitors: a combination of pharmacophore and 3D-QSAR modeling, virtual screening, molecular docking, and pharmacokinetic analysis. Badhani B; Kakkar R J Biomol Struct Dyn; 2017 Jul; 35(9):1950-1967. PubMed ID: 27401212 [TBL] [Abstract][Full Text] [Related]
17. Design of Novel Chemotherapeutic Agents Targeting Checkpoint Kinase 1 Using 3D-QSAR Modeling and Molecular Docking Methods. Balupuri A; Balasubramanian PK; Cho SJ Curr Comput Aided Drug Des; 2016; 12(4):302-313. PubMed ID: 27585602 [TBL] [Abstract][Full Text] [Related]
18. Kinase Inhibitory Activities and Molecular Docking of a Novel Series of Anticancer Pyrazole Derivatives. Nossier ES; Abd El-Karim SS; Khalifa NM; El-Sayed AS; Hassan ESI; El-Hallouty SM Molecules; 2018 Nov; 23(12):. PubMed ID: 30477238 [TBL] [Abstract][Full Text] [Related]
19. ANN-QSAR model for virtual screening of androstenedione C-skeleton containing phytomolecules and analogues for cytotoxic activity against human breast cancer cell line MCF-7. Prakash O; Khan F; Sangwan RS; Misra L Comb Chem High Throughput Screen; 2013 Jan; 16(1):57-72. PubMed ID: 23030276 [TBL] [Abstract][Full Text] [Related]
20. Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling. Zalloum H; Tayyem R; Irmaileh BA; Bustanji Y; Zihlif M; Mohammad M; Rjai TA; Mubarak MS J Mol Graph Model; 2015 Sep; 61():61-84. PubMed ID: 26188796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]